BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T154320
CREATED:20201021T150805Z
LAST-MODIFIED:20201021T150805Z
UID:27572-1613952000-1614297599@www.pharmajournalist.com
SUMMARY:Gene Therapy for Rare Disorders USA
DESCRIPTION:The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. \nWith investment at an all-time high\, and several indications in late-stage trials gearing up for approval\, the meeting will leverage the experience from first to market pioneers\, as well as unveiling the strategies drug developers are employing to improve efficacy\, safety and commercial viability. \n \nIncorporating insights from 90+ industry-leading speakers\, this digital conference will delve into the key regulatory\, reimbursement\, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies. \nJoin 500+ of your colleagues online to accelerate the progress of the next generation of gene therapies. \nThis is your comprehensive guide to define your commercial path forward.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-rare-disorders-usa/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T154320
CREATED:20201109T080924Z
LAST-MODIFIED:20201109T081324Z
UID:27836-1614038400-1614297599@www.pharmajournalist.com
SUMMARY:RAS – Targeted Drug Discovery – Digital Summit
DESCRIPTION:Recent clinical advancements of KRAS G12C inhibitors have generated increased interest in the fight to bring an end to RAS driven cancers. However\, their specificity to only target G12C mutations\, leaves huge untapped therapeutic potential to target all RAS driven cancers beyond the lungs. This calls for continued research efforts by industry and academic experts alike. \n \nThe Digital RAS- Targeted Drug Discovery Summit is the premium forum for cellular\, preclinical and translational RAS experts to explore potential strategies to tackle undrugged RAS oncogenes beyond KRAS G12C. \nAs part of our industry leading and dedicated RAS conference series\, this exciting next iteration is shining the spotlight on: \n§     Identifying key learnings from known pre-clinical and clinical data for viable KRAS direct inhibitors to effectively drug all RAS isoforms \n§     Exploring G12C pre-clinical and clinical data to optimise future RAS targeting strategies \n§     Learning from the patterns of RAS mutations to understand prognostic or predictive power in various cancer types beyond lung cancer \nJoin senior experts from leading biotech\, large pharma and pioneering academic institutions at the Digital RAS- Targeted Drug Discovery Summit as they identify future models and strategies for streamlining anti-RAS therapeutics into the clinic. \nTo know more about RAS – Targeted Drug Discovery please click here.
URL:https://www.pharmajournalist.com/event/ras-targeted-drug-discovery-digital-summit/
LOCATION:Digital Event\, GMT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T154320
CREATED:20201111T111739Z
LAST-MODIFIED:20201111T111739Z
UID:27882-1614038400-1614297599@www.pharmajournalist.com
SUMMARY:9th Neurodegenerative Drug Development Summit
DESCRIPTION:The 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating translational challenges by shining a light on pioneering companies leading the way to meet this dire medical need. \n \nBuilding on the success of last year’s meeting\, this year’s program showcases new biotechs trailblazing this space and will put the spotlight on the latest scientific advances in terms of diverse targets\, novel modalities and innovative trial design. Across 3 action-packed\, case-study driven days and 2 parallel tracks of learning\, we present the opportunity to join us online in 2021 to overcome technical and operational challenges preventing you and your team from translating promising preclinical research into evidenced clinical benefit. \nWhether you are working in a team dedicated to Parkinson’s\, Alzheimer’s\, ALS\, Frontotemporal Dementia or a rare neurodegenerative disorder\, join this intimate\, industry-led forum to not only to learn from those spearheading this space\, but to network and build meaningful partnerships with over 180 neurodegenerative drug development experts. \nTo know more about 9th Neurodegenerative Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/9th-neurodegenerative-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR